Simabs SA
11.4 FTEThe score of Simabs shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +270 % Total assets +125 % Headcount (avg FTE) +159 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Simabs's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jul 2026
- Year ended 31 Dec 2024filed on 23 Jul 2025
- Year ended 31 Dec 2023filed on 29 Jul 2024
- Year ended 31 Dec 2022filed on 30 Jul 2023
- Year ended 31 Dec 2021filed on 03 Jul 2022
Simabs's financial analysis
- Solvency37.6%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Simabs
Simabs's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0732.709.096
- VAT number
- BE0732709096
- Peppol
- Registered · 0208:0732709096 · as of 27 Oct 2026
- Legal form
- SA
- Incorporated
- 20 Aug 2019
- Registered office
- 3590 Diepenbeek
- Size
- Small · 11.4 FTE
- Latest accounts
- 2025 · filed on 30 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Simabs (SA) has been based in Diepenbeek since 2019, active in: manufacture of medicaments. For 2025, it reports a net loss of €1.47m and equity of €1.00m; its revenue is not published. With 11.4 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 37.6%, below the median of its sector (47.2%).
Companies similar to Simabs
Companies in the same business, of comparable size and area, outside its group.
- Perseus Biomics Manufacture of basic pharmaceutical products Leuven · balance sheet €5.25m
- Rejuvenate Biomed Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet €3.45m
- Curium PET Liège Manufacture of basic pharmaceutical products Liège · balance sheet €1.86m
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- Boehringer Ingelheim Veterinary Medicine Belgium NV Research and experimental development on natural sciences and engineering Evergem · balance sheet €6.51m
- ILiAD Biotechnologies Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.06m
- Temmune Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet €3.43m
- anicells Manufacture of pharmaceutical preparations Niel · balance sheet €1.82m
Frequently asked questions about Simabs
What is the revenue of Simabs?
Simabs files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Simabs?
In Belgium, the VAT number is the company number prefixed with BE: BE0732709096 for Simabs, if the company is VAT-registered. Its company number (CBE) is 0732.709.096.
Where is the registered office of Simabs?
According to the CBE register, the registered office of Simabs is in 3590 Diepenbeek.
What is the equity of Simabs?
At the close of the 2025 financial year, the equity of Simabs amounts to 1,003,251 €, a solvency of 37.6% of total assets.
How many people work at Simabs?
11.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Simabs?
The register lists 12 active mandates at Simabs. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Simabs
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →